What to expect in the days after a ChondroFiller injection

Swelling, a flare in pain, and joint stiffness in the hours after a ChondroFiller injection are predictable — and expected. They are not signs that something has gone wrong. They reflect the joint's physiological response to an intra-articular collagen scaffold: the surrounding tissue reacts to new material being placed within the joint space, producing the same localised inflammatory signals it would for any accurately delivered intra-articular procedure.

For most patients, these symptoms appear within the first few hours and reach their peak somewhere between 24 and 72 hours after the injection. By that point, the discomfort typically begins to ease on its own, without any specific intervention.

The 72-hour mark is a practical benchmark worth holding in mind. In the days immediately after treatment, symptoms that are gradually settling — even if still uncomfortable — are following the expected pattern. Symptoms that are worsening, or that have not started to improve by the end of that window, are the signal to make contact with the clinical team. Specifically, increasing joint warmth, progressive redness, or swelling that continues to build beyond 72 hours should prompt a prompt review, as should any fever.

Think of the first three days as a monitoring window rather than a recovery period — the scaffold is setting in place, the joint is responding, and predictable discomfort is part of that process.

Risks that do need clinical attention

Five distinct clinical risks sit above the expected post-injection course described above — each worth understanding separately, and each managed differently.

Infection carries the same risk profile as any intra-articular injection. The warning signs to act on are escalating joint warmth, progressive redness, and swelling that continues to build beyond 72 hours rather than settling — or the development of a fever. These findings warrant same-day contact with the clinical team.

Murine collagen hypersensitivity is the product-specific risk that makes pre-procedure allergy screening non-negotiable. ChondroFiller uses Type I collagen extracted from rat-tail tendon by a non-enzymatic weak-acid process; the murine origin is precisely why clinicians screen for animal-collagen hypersensitivity before the injection takes place. Screening is what prevents this reaction from occurring — not a formality, but the clinical safeguard.

Gel displacement and fibrous tissue formation are tied primarily to technique rather than patient behaviour. A 2025 wrist study by Matta et al. found that fibrous tissue formation occurred only in overfilled defects; flush application eliminated the risk entirely. The primary prevention lever here sits with the treating clinician.

Early mechanical loading adds a patient-side consideration. A 2024 in-vitro biomechanical study found that in the hours immediately after placement, the scaffold does not yet have sufficient mechanical stability to protect the opposing cartilage surface under cyclic loading. Post-procedure movement restrictions exist for this reason — as a direct response to the scaffold's gelation timeline, not an abstract precaution.

Non-gelation — failure of the scaffold to set — is documented in the clinical record but remains exceptional. Across more than 19,000 treated cases compiled in Meidrix Biomedicals' post-market surveillance, the overall device complaint rate sits at approximately 0.06%, with zero serious adverse device effects recorded.

How ChondroFiller injection risk compares to surgical alternatives

Published complication data place the ChondroFiller injection in a different risk bracket to the surgical alternatives most patients will be weighing. Across the manufacturer's post-market surveillance programme, serious adverse device effects have not been recorded; the reoperation rate sits at 3–8%. For context, ACI and MACI carry reported complication rates of up to 17% and reoperation rates reaching 37%; microfracture reoperation rates extend to 41%. These are the published figures — a concrete reference point when comparing an outpatient injectable pathway against theatre-based alternatives.

The evidence base behind those figures is large but not independent. The surveillance data originate from Meidrix Biomedicals' own post-market clinical follow-up programme, and no blinded, independently conducted randomised controlled trial has been published for ChondroFiller. Clinical sources are consistent in acknowledging this limitation, and the complication percentages should be read with that context in mind.

On regulatory classification — and what it means in practice for UK patients — ChondroFiller holds CE Class III status under EU MDR, the highest-risk device category, which demands the most rigorous pre-market conformity assessment before approval. It is not FDA-approved. In the UK it is available only under individual prescription and receives no NHS funding, making it a private-access treatment. Patients considering the procedure through the London Cartilage Clinic on Harley Street should factor both access route and cost into their planning from the outset.

Which patients are suitable for ChondroFiller injection

Eligibility rests on four factors: the depth of cartilage damage, how the damage is distributed, the severity of any underlying arthritis, and the patient's general health profile.

Depth of damage

The formal CE-mark indication covers ICRS or Outerbridge Grade III and Grade IV lesions. In plain terms, Grade III means cartilage damage that runs deep but stops short of bone; Grade IV means the full thickness of cartilage has been lost, leaving bone exposed. Both are within the licensed range. Grade I and II lesions — surface-level softening or superficial fraying — do not meet the threshold, because the scaffold's mechanism depends on meaningful structural loss to recruit the body's own repair cells effectively.

Two eligibility tracks

Focal-defect track. Patients with a contained lesion — typically up to 6 cm², arising from sports injury, osteochondritis dissecans (OCD), or trauma — follow a focused repair pathway. The scaffold fills and stabilises the defined defect site.

Diffuse-OA injectable track. This is the track that sets ChondroFiller injection apart from surgical cartilage-repair alternatives. Eligibility extends across Kellgren-Lawrence Grades I to IV, including presentations described as 'bone on bone' — presentations that most surgical cartilage-repair procedures would decline to take on.

Age

There is no formal upper age limit. Active adults roughly in the 40–65 range tend to show the strongest regenerative response, but both younger patients with post-traumatic damage and older patients with symptomatic joint wear are within scope.

Where ChondroFiller injection sits in the pathway

Most patients referred for assessment have already worked through physiotherapy and symptomatic injections without sufficient relief. ChondroFiller injection typically enters the picture at the cartilage-restoration stage — the step before joint replacement becomes the realistic conversation.

Who ChondroFiller injection is not suitable for

Not every patient with Grade III or IV cartilage damage will be suitable, and understanding where the limits fall — and why — avoids an assessment that leads nowhere.

Hard exclusions

These are non-negotiable safety calls:

• Known hypersensitivity to animal collagen. As covered in the risks section, ChondroFiller's Type I collagen is extracted from rat-tail tendon. A confirmed sensitivity to animal-derived collagen closes the door entirely — there is no clinical workaround.
• Active joint or systemic infection. Placing a scaffold into an infected environment risks seeding or worsening the infection.
• Active inflammatory arthritis flare — for example, an acute rheumatoid episode — disrupts the local conditions the scaffold requires to gel and integrate.
• Pregnancy or breastfeeding; active malignancy.

Relative exclusions — where an additional step may help

Severe mechanical malalignment (significant varus or valgus deformity) may require a corrective osteotomy before or alongside the injection to give the scaffold a viable mechanical environment. This is a sequencing question, not a permanent barrier.

Where end-stage tricompartmental OA has progressed to the point where total joint replacement is the only realistic option, ChondroFiller injection is unlikely to add meaningful benefit.

Hip-specific caution

A 2021 cohort study reported poor outcomes specifically in patients with Tönnis Grade 2–3 hip OA. Seventeen of twenty-one patients with earlier-stage hip disease achieved good or excellent results — so this is a subgroup signal requiring careful pre-procedure review, not a blanket hip exclusion.

Surgical unsuitability is not itself a disqualifier

Because the current pathway is an outpatient ultrasound-guided injection rather than an operative procedure, it extends eligibility beyond what arthroscopic or theatre-based cartilage repair can offer. Patients who cannot tolerate general anaesthesia or surgery for medical reasons may still qualify — the exclusions above relate to the scaffold and the joint environment, not to surgical fitness.

Getting assessed at the London Cartilage Clinic

The picture that emerges from this evidence is of a treatment with a clearly defined risk profile and meaningful — if narrow — eligibility criteria. A formal assessment at the London Cartilage Clinic on Harley Street maps those criteria to the individual: lesion grade on MRI, defect size and distribution, joint loading pattern, and the exclusion checklist covered above; nothing is recommended until each factor is established. Professor Paul Y. F. Lee leads the Liquid Cartilage™ service at the clinic — the UK certified delivery centre for ChondroFiller injection — and assessments can be arranged at londoncartilage.com. Placement technique is a direct determinant of outcome, which is why the assessment stage matters as much as the procedure itself: the scaffold must be applied flush, at the right volume, and into a mechanically sound environment.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002